Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03301896
Title Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

head and neck squamous cell carcinoma

melanoma

Therapies

LHC165 + Spartalizumab

LHC165

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Los Angeles California 90095 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Novartis Investigative Site Wilrijk 2610 Belgium Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Chuo ku Tokyo 104 0045 Japan Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field